Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Trimethyllysine (TML) has been identified as a predictor of incident cardiovascular disease (CVD) risk and is associated with an increased risk of Cardiovascular diseases (CVD) and cardiovascular mortality.
Plasma Trimethyllysine levels, alone and together with Trimethylamine-N-Oxide (TMAO), are associated with both near- and long-term Cardiovascular events in patients with chest pain and acute coronary syndromes (ACS).
Trimethyllysine is a precursor to trimethylamine N-oxide (TMAO).
However, Trimethyllysine does not appear to be a major microbial source fo…